A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors
Neoplasms
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 42 (final count)
- Started
- Oct 24, 2023
- Main results expected
- Jun 30, 2026
- Fully finished
- Jun 30, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1 - Proportion of Participants with Dose Limiting Toxicities (DLTs) during DLT Observation Period
Measured over: Up to 28 days
Part 1 - Proportion of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) based on Severity during DLT Observation Period
Measured over: Up to 28 days
Part 1 - Duration of Treatment Emergent AEs and SAEs (Days) during DLT Observation Period
Measured over: Up to 28 days
Part 1 - Percentage of Participants who receive all Planned Doses during DLT Observation Period
Measured over: Up to 28 days
Part 1 -Percentage of Participants who require dosage interruptions, dose reductions, and drug discontinuations due to adverse reactions during DLT Observation Period
Measured over: Up to 28 days
Part 2 - Confirmed Objective Response Rate (ORR)
Measured over: Up to approximately 52 weeks
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06077877 · record last updated 2026-04-24 · checked 2026-11-09 15:47 UTC